Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

1246P - Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing

Date

21 Oct 2023

Session

Poster session 14

Topics

Cancer Biology;  Cancer Intelligence (eHealth, Telehealth Technology, BIG Data);  Cancer Diagnostics;  Cancer Research

Tumour Site

Presenters

Juan Blanco Heredia

Citation

Annals of Oncology (2023) 34 (suppl_2): S711-S731. 10.1016/S0923-7534(23)01942-7

Authors

J. Blanco Heredia1, B.H. Diplas2, O.S.M. El Nahhas3, P. Selenica4, F. Pareja5, D. Mandelker6, B. Weigelt1, N. Riaz7, E. Rosen8, A. Sfeir9, J.S. Reis-Filho1

Author affiliations

  • 1 Department Of Pathology And Laboratory Medicine, MSKCC - Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 Department Of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 10017 - New York/US
  • 3 Clinical Ai, EKFZ - Else Kröner Fresenius Zentrum für Digitale Gesundheit, 01307 - Dresden/DE
  • 4 Department Of Pathology And Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 5 Department Of Pathology, MSKCC - Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 6 Pathology, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 7 Radiation Oncology, Memorial Sloan Kettering 60th Street Outpatient Center, 10022 - New York/US
  • 8 Early Drug Development, Breast Medicine, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 9 Molecular Biology Program, Memorial Sloan Kettering Cancer Center, 10065 - New York/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1246P

Background

Alternative Lengthening of Telomeres (ALT) is a telomerase-independent mechanism for the maintenance of telomeres, which is characterized by the absence of telomerase activity and often co-occurring loss of function somatic mutations in ATRX or DAXX. There is burgeoning evidence to suggest that ALT is associated with genetic vulnerabilities that may be exploited through synthetically lethal approaches. Here, we sought to develop a classifier to detect ALT based on multi-gene targeted sequencing data.

Methods

We developed an attention-based neural network model to detect ALT based on a clinical tumor-normal panel sequencing data (MSK-IMPACT). For training, cases with deleterious ATRX or DAXX mutations were considered ALT (n=274), whereas cases harboring TERT promoter hotspot mutations or gene amplification were regarded as non-ALT (n=965). The model was trained using a 10-fold cross-validation and 997 genetic and clinical features, including cancer type, telomeric content and fusion rates, copy number variation and mutational profiles, followed by hyperparameters optimization. The model was independently validated in 619 cases across 36 cancer types with an ALT:non-ALT ratio of 1:3.

Results

In the validation cohort, the MLP classifier detected ALT cancers with an accuracy of 80% (99% CI 75.9-84.1%), a sensitivity of 69% (99% CI 64.2-74.8%), specificity of 88% (99% CI 84.6-91.4%), and a F1 score of 75% (99% CI 70.5-79.5%). In the context of samples correctly classified (n=495), ALT was significantly more frequently detected in GI neuroendocrine tumors, uterine sarcomas, as well as adrenocortical, prostate and small cell lung cancer.

Conclusions

Deep learning can detect ALT cancers from targeted sequencing data across various cancer types. This new method enables the dissection of genomic and phenotypic characteristics of ALT cancers in large retrospective cohorts with available targeted sequencing data, while providing a potentially high-throughput, accessible means to enroll patients in prospective studies targeting the ALT phenotype.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Memorial Sloan Kettering Cancer Center.

Funding

NIH K12.

Disclosure

B.H. Diplas: Non-Financial Interests, Personal and Institutional, Research Funding: NIH K12, MSK FGI. B. Weigelt: Financial Interests, Personal, Funding: Repare Therapeutics. E. Rosen: Financial Interests, Personal and Institutional, Research Funding: Bayer. A. Sfeir: Financial Interests, Personal, Advisory Board, Shareholder, Co-Founder, Consultant: Repare Therapeutics. J.S. Reis-Filho: Financial Interests, Personal, Other, Consultant: Goldman Sachs, Eli Lilly, Saga Diagnostics; Financial Interests, Personal, Other, Member of the Scientific Advisory Board and Consultant: Repare Therapeutics, Paige.AI; Financial Interests, Personal, Advisory Board: Personalis, Roche Tissue Diagnostics; Financial Interests, Personal, Advisory Board, Member of the Scientific Advisory Board: Bain Capital; Financial Interests, Personal, Advisory Board, Ad hoc member of the Pathology Scientific Advisory Board: Daiichi Sankyo, Merck; Financial Interests, Personal, Advisory Board, Ad hoc member of the Oncology Scientific Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board, Member of the SAB: MultiplexDX; Financial Interests, Personal, Member of Board of Directors: Odyssey Bio, Grupo Oncoclinicas; Financial Interests, Personal, Stocks/Shares: Repare Therapeutics; Financial Interests, Personal, Other, Stock options: Paige.AI. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.